Additionally, PD-L1 inhibitors have been approved in combination with chemotherapy by the U.S. FDA for first line management of extensive-stage small cell lung cancer (SCLC), while PD-1 inhibitors are currently approved in third or later-line treatment settings for metastatic SCLC (Table 1). The gene discussed is CD274; the disease is small cell lung carcinoma.